New research estimates 24% of cancers in men that were detected in 2012 were overdiagnosed, meaning they never would have caused harm if left untreated.
Labelling very low-risk conditions as cancers can cause unnecessary anxiety and lead to overtreatment.
Since the 1980s, PSA tests have been used for the diagnosis and follow-up of prostate cancer. However, its use as a screening test for prostate cancer remains controversial.
A family physician and public health researcher explains why he isn’t getting a prostate cancer test in Movember or at any time in the near future.
Two major studies cast doubt on the value of screening for prostate cancer, yet it continues regardless.
In news which may come as a relief to apprehensive men and short-fingered doctors alike, guidelines are now changing.
Screening may save lives but it comes with a cost - and sometimes unbearable decisions - that shouldn’t be underestimated.
Researchers have been talking about the dangers of overdiagnosis for some time. But now a national survey shows most people aren’t told about the risk it poses to their health – and they want to know.